Meeting
2019 ASCO Annual Meeting
PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
Authors
Juanita Suzanne Lopez
Drug Development Unit-The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Juanita Suzanne Lopez , Manuel SelviMiralles , Malaka Ameratunga , Anna Minchom , Javier Pascual , Udai Banerji , Hannah Bye , Florence I. Raynaud , Karen E Swales , Jason Malia , Michael Hubank , Isaac Garcia-Murillas , Mona Parmar , Sarah Emily Ward , Laura Finneran , Emma Hall , Alison Joanne Turner , Johann S. De Bono , Timothy A Yap , Nicholas C. Turner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT02389842
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3087)
DOI
10.1200/JCO.2019.37.15_suppl.3087
Abstract #
3087
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.
First Author: Javier Pascual
Poster
2017 ASCO Annual Meeting
A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.
First Author: Joline Si Jing Lim
Poster
2012 ASCO Annual Meeting
A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.
First Author: Aurelius Gabriel Omlin
Poster
2018 ASCO Annual Meeting
A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.
First Author: Romualdo Barroso-Sousa